1
|
Mah N, Kurtz A, Fuhr A, Seltmann S, Chen Y, Bultjer N, Dewender J, Lual A, Steeg R, Mueller SC. The Management of Data for the Banking, Qualification, and Distribution of Induced Pluripotent Stem Cells: Lessons Learned from the European Bank for Induced Pluripotent Stem Cells. Cells 2023; 12:2756. [PMID: 38067184 PMCID: PMC10705942 DOI: 10.3390/cells12232756] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2023] [Revised: 11/17/2023] [Accepted: 11/20/2023] [Indexed: 12/18/2023] Open
Abstract
The European Bank for induced pluripotent Stem Cells (EBiSC) was established in 2014 as a non-profit project for the banking, quality control, and distribution of human iPSC lines for research around the world. EBiSC iPSCs are deposited from diverse laboratories internationally and, hence, a key activity for EBiSC is standardising not only the iPSC lines themselves but also the data associated with them. This includes enabling unique nomenclature for the cells, as well as applying uniformity to the data provided by the cell line generator versus quality control data generated by EBiSC, and providing mechanisms to share personal data in a secure and GDPR-compliant manner. A joint approach implemented by EBiSC and the human pluripotent stem cell registry (hPSCreg®) has provided a solution that enabled hPSCreg® to improve its registration platform for iPSCs and EBiSC to have a pipeline for the import, standardisation, storage, and management of data associated with EBiSC iPSCs. In this work, we describe the experience of cell line data management for iPSC banking throughout the course of EBiSC's development as a central European banking infrastructure and present a model for how this could be implemented by other iPSC repositories to increase the FAIRness of iPSC research globally.
Collapse
Affiliation(s)
- Nancy Mah
- Fraunhofer-Institute für Biomedizinische Technik (IBMT), Joseph-von-Fraunhofer Weg 1, 66280 Sulzbach, Germany; (N.M.)
| | - Andreas Kurtz
- Fraunhofer-Institute für Biomedizinische Technik (IBMT), Joseph-von-Fraunhofer Weg 1, 66280 Sulzbach, Germany; (N.M.)
- Berlin Institute of Health Center for Regenerative Therapies, Augustenburger Platz 1, 13353 Berlin, Germany
| | - Antonie Fuhr
- Fraunhofer-Institute für Biomedizinische Technik (IBMT), Joseph-von-Fraunhofer Weg 1, 66280 Sulzbach, Germany; (N.M.)
| | - Stefanie Seltmann
- Fraunhofer-Institute für Biomedizinische Technik (IBMT), Joseph-von-Fraunhofer Weg 1, 66280 Sulzbach, Germany; (N.M.)
| | - Ying Chen
- Fraunhofer-Institute für Biomedizinische Technik (IBMT), Joseph-von-Fraunhofer Weg 1, 66280 Sulzbach, Germany; (N.M.)
| | - Nils Bultjer
- Fraunhofer-Institute für Biomedizinische Technik (IBMT), Joseph-von-Fraunhofer Weg 1, 66280 Sulzbach, Germany; (N.M.)
| | - Johannes Dewender
- Fraunhofer-Institute für Biomedizinische Technik (IBMT), Joseph-von-Fraunhofer Weg 1, 66280 Sulzbach, Germany; (N.M.)
| | - Ayuen Lual
- European Collection of Authenticated Cell Cultures (ECACC), UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK;
| | - Rachel Steeg
- Fraunhofer UK Research Ltd., Technology and Innovation Centre, 99 George St., Glasgow G1 1RD, UK
| | - Sabine C. Mueller
- Fraunhofer-Institute für Biomedizinische Technik (IBMT), Joseph-von-Fraunhofer Weg 1, 66280 Sulzbach, Germany; (N.M.)
| |
Collapse
|
2
|
Wihan J, Karnatz I, Sébastien I, Kettenhofen R, Schmid B, Clausen C, Fischer B, Steeg R, Zimmermann H, Neubauer JC. Production of Human Neurogenin 2-Inducible Neurons in a Three-Dimensional Suspension Bioreactor. J Vis Exp 2023. [PMID: 37010312 DOI: 10.3791/65085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/19/2023] Open
Abstract
The derivation of neuronal lineage cells from human induced pluripotent stem cells (hiPSCs) marked a milestone in brain research. Since their first advent, protocols have been continuously optimized and are now widely used in research and drug development. However, the very long duration of these conventional differentiation and maturation protocols and the increasing demand for high-quality hiPSCs and their neural derivatives raise the need for the adoption, optimization, and standardization of these protocols to large-scale production. This work presents a fast and efficient protocol for the differentiation of genetically modified, doxycycline-inducible neurogenin 2 (iNGN2)-expressing hiPSCs into neurons using a benchtop three-dimensional (3D) suspension bioreactor. In brief, single-cell suspensions of iNGN2-hiPSCs were allowed to form aggregates within 24 h, and neuronal lineage commitment was induced by the addition of doxycycline. Aggregates were dissociated after 2 days of induction and cells were either cryopreserved or replated for terminal maturation. The generated iNGN2 neurons expressed classical neuronal markers early on and formed complex neuritic networks within 1 week after replating, indicating an increasing maturity of neuronal cultures. In summary, a detailed step-by-step protocol for the fast generation of hiPSC-derived neurons in a 3D environment is provided that holds great potential as a starting point for disease modeling, phenotypic high-throughput drug screenings, and large-scale toxicity testing.
Collapse
Affiliation(s)
- Jeanette Wihan
- Fraunhofer Project Center for Stem Cell Process Engineering, Fraunhofer Institute for Biomedical Engineering IBMT
| | - Isabell Karnatz
- Fraunhofer Project Center for Stem Cell Process Engineering, Fraunhofer Institute for Biomedical Engineering IBMT
| | - Isabelle Sébastien
- Fraunhofer Project Center for Stem Cell Process Engineering, Fraunhofer Institute for Biomedical Engineering IBMT
| | - Ralf Kettenhofen
- Fraunhofer Project Center for Stem Cell Process Engineering, Fraunhofer Institute for Biomedical Engineering IBMT
| | | | | | - Benjamin Fischer
- Fraunhofer Project Center for Stem Cell Process Engineering, Fraunhofer Institute for Biomedical Engineering IBMT
| | - Rachel Steeg
- Fraunhofer UK Research Ltd, Technology and Innovation Centre
| | - Heiko Zimmermann
- Fraunhofer Project Center for Stem Cell Process Engineering, Fraunhofer Institute for Biomedical Engineering IBMT; Fraunhofer Institute for Biomedical Engineering IBMT; Department of Molecular and Cellular Biotechnology, Saarland University; Facultad de Ciencias del Mar, Universidad Católica del Norte
| | - Julia C Neubauer
- Fraunhofer Project Center for Stem Cell Process Engineering, Fraunhofer Institute for Biomedical Engineering IBMT; Fraunhofer Institute for Biomedical Engineering IBMT;
| |
Collapse
|
3
|
Kwok CK, Sébastien I, Hariharan K, Meiser I, Wihan J, Altmaier S, Karnatz I, Bauer D, Fischer B, Feile A, Cabrera-Socorro A, Rasmussen M, Holst B, Neubauer JC, Clausen C, Verfaillie C, Ebneth A, Hansson M, Steeg R, Zimmermann H. Scalable expansion of iPSC and their derivatives across multiple lineages. Reprod Toxicol 2022; 112:23-35. [PMID: 35595152 DOI: 10.1016/j.reprotox.2022.05.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2021] [Revised: 05/10/2022] [Accepted: 05/13/2022] [Indexed: 12/30/2022]
Abstract
Induced pluripotent stem cell (iPSC) technology enabled the production of pluripotent stem cell lines from somatic cells from a range of known genetic backgrounds. Their ability to differentiate and generate a wide variety of cell types has resulted in their use for various biomedical applications, including toxicity testing. Many of these iPSC lines are now registered in databases and stored in biobanks such as the European Bank for induced pluripotent Stem Cells (EBiSC), which can streamline the quality control and distribution of these individual lines. To generate the quantities of cells for banking and applications like high-throughput toxicity screening, scalable and robust methods need to be developed to enable the large-scale production of iPSCs. 3D suspension culture platforms are increasingly being used by stem cell researchers, owing to a higher cell output in a smaller footprint, as well as simpler scaling by increasing culture volume. Here we describe our strategies for successful scalable production of iPSCs using a benchtop bioreactor and incubator for 3D suspension cultures, while maintaining quality attributes expected of high-quality iPSC lines. Additionally, to meet the increasing demand for "ready-to-use" cell types, we report recent work to establish robust, scalable differentiation protocols to cardiac, neural, and hepatic fate to enable EBiSC to increase available research tools.
Collapse
Affiliation(s)
- Chee Keong Kwok
- Cell Therapy R&D, Novo Nordisk A/S, Novo Nordisk Park 1, 2760 Måløv, Denmark
| | - Isabelle Sébastien
- Fraunhofer Project Center for Stem Cell Process Engineering, Fraunhofer Institute for Biomedical Engineering IBMT, Neunerplatz 2, 97082 Würzburg, Germany
| | - Krithika Hariharan
- Fraunhofer Project Center for Stem Cell Process Engineering, Fraunhofer Institute for Biomedical Engineering IBMT, Neunerplatz 2, 97082 Würzburg, Germany
| | - Ina Meiser
- Fraunhofer Institute for Biomedical Engineering IBMT, Joseph-von-Fraunhofer-Weg 1, 66820 Sulzbach, Germany
| | - Jeanette Wihan
- Fraunhofer Project Center for Stem Cell Process Engineering, Fraunhofer Institute for Biomedical Engineering IBMT, Neunerplatz 2, 97082 Würzburg, Germany
| | - Saskia Altmaier
- Fraunhofer Institute for Biomedical Engineering IBMT, Joseph-von-Fraunhofer-Weg 1, 66820 Sulzbach, Germany
| | - Isabell Karnatz
- Fraunhofer Project Center for Stem Cell Process Engineering, Fraunhofer Institute for Biomedical Engineering IBMT, Neunerplatz 2, 97082 Würzburg, Germany
| | - Dominic Bauer
- Fraunhofer Project Center for Stem Cell Process Engineering, Fraunhofer Institute for Biomedical Engineering IBMT, Neunerplatz 2, 97082 Würzburg, Germany
| | - Benjamin Fischer
- Fraunhofer Project Center for Stem Cell Process Engineering, Fraunhofer Institute for Biomedical Engineering IBMT, Neunerplatz 2, 97082 Würzburg, Germany
| | - Alexander Feile
- Fraunhofer Project Center for Stem Cell Process Engineering, Fraunhofer Institute for Biomedical Engineering IBMT, Neunerplatz 2, 97082 Würzburg, Germany
| | - Alfredo Cabrera-Socorro
- Neuroscience Therapeutic Area, Janssen Research & Development, Turnhoutseweg 30, 2340 Beerse, Belgium
| | | | - Bjørn Holst
- Bioneer A/S, Kogle Allé 2, 2970 Hørsholm, Denmark
| | - Julia C Neubauer
- Fraunhofer Project Center for Stem Cell Process Engineering, Fraunhofer Institute for Biomedical Engineering IBMT, Neunerplatz 2, 97082 Würzburg, Germany; Fraunhofer Institute for Biomedical Engineering IBMT, Joseph-von-Fraunhofer-Weg 1, 66820 Sulzbach, Germany
| | | | - Catherine Verfaillie
- Department of Development and Regeneration, Stem Cell Institute, UZ Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
| | - Andreas Ebneth
- Neuroscience Therapeutic Area, Janssen Research & Development, Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Mattias Hansson
- Cell Therapy R&D, Novo Nordisk A/S, Novo Nordisk Park 1, 2760 Måløv, Denmark
| | - Rachel Steeg
- Fraunhofer UK Research Ltd, Technology and Innovation Centre, 99 George Street, G1 1RD Glasgow, United Kingdom
| | - Heiko Zimmermann
- Fraunhofer Project Center for Stem Cell Process Engineering, Fraunhofer Institute for Biomedical Engineering IBMT, Neunerplatz 2, 97082 Würzburg, Germany; Fraunhofer Institute for Biomedical Engineering IBMT, Joseph-von-Fraunhofer-Weg 1, 66820 Sulzbach, Germany; Department of Molecular and Cellular Biotechnology, Saarland University, 66123 Saarbrücken, Germany; Facultad de Ciencias del Mar, Universidad Católica del Norte, Coquimbo, Chile.
| |
Collapse
|
4
|
Steeg R, Mueller SC, Mah N, Holst B, Cabrera-Socorro A, Stacey GN, De Sousa PA, Courtney A, Zimmermann H. EBiSC best practice: How to ensure optimal generation, qualification, and distribution of iPSC lines. Stem Cell Reports 2021; 16:1853-1867. [PMID: 34380020 PMCID: PMC8365092 DOI: 10.1016/j.stemcr.2021.07.009] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2020] [Revised: 07/07/2021] [Accepted: 07/07/2021] [Indexed: 12/24/2022] Open
Abstract
Disease-relevant human induced pluripotent stem cells (iPSCs) are generated worldwide for research purposes; however, without robust and practical ethical, legal, and quality standards, there is a high risk that their true potential will not be realized. Best practices for tissue procurement, iPSC reprogramming, day-to-day cultivation, quality control, and data management aligned with an ethical and legal framework must be included into daily operations to ensure their promise is maximized. Here we discuss key learning experiences from 7 years of operating the European Bank for induced Pluripotent Stem Cells (EBiSC) and recommend how to incorporate solutions into a daily management framework. Ethics for iPSCs must be explicit, GDPR compliant, and allow future research iPSC use restrictions are linked to consent, reprogramming, and gene editing Quality control must be implemented from primary tissue handling onward Robust data management is essential to ensure privacy and enable data sharing
Collapse
Affiliation(s)
| | - Sabine C Mueller
- Fraunhofer Institute for Biomedical Engineering (IBMT), Joseph-von-Fraunhofer-Weg 1, 66280 Sulzbach, Germany
| | - Nancy Mah
- Fraunhofer Institute for Biomedical Engineering (IBMT), Joseph-von-Fraunhofer-Weg 1, 66280 Sulzbach, Germany
| | - Bjørn Holst
- Bioneer A/S, Kogle Alle 2, 2970 Hørsholm, Denmark
| | - Alfredo Cabrera-Socorro
- Neuroscience Department, Janssen Research and Development, Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Glyn N Stacey
- International Stem Cell Banking Initiative, 2 High Street, Barley, Herts SG88HZ, UK; National Stem Cell Resource Centre, Institute of Zoology, Chinese Academy of Sciences, Beijing 100190, China; Innovation Academy for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing 100101, China
| | - Paul A De Sousa
- Paul A. De Sousa, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh EH16 4SB, UK
| | | | - Heiko Zimmermann
- Fraunhofer Institute for Biomedical Engineering (IBMT), Joseph-von-Fraunhofer-Weg 1, 66280 Sulzbach, Germany; Molecular and Cellular Biotechnology/Nanotechnology, Saarland University, 66123 Saarbrücken, Germany; Facultad de Ciencias del Mar, Universidad Católica del Norte, Coquimbo, Chile.
| |
Collapse
|
5
|
Shih PY, Kreir M, Kumar D, Seibt F, Pestana F, Schmid B, Holst B, Clausen C, Steeg R, Fischer B, Pita-Almenar J, Ebneth A, Cabrera-Socorro A. Development of a fully human assay combining NGN2-inducible neurons co-cultured with iPSC-derived astrocytes amenable for electrophysiological studies. Stem Cell Res 2021; 54:102386. [PMID: 34229210 DOI: 10.1016/j.scr.2021.102386] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/02/2020] [Revised: 03/15/2021] [Accepted: 04/30/2021] [Indexed: 11/19/2022] Open
Abstract
Neurogenin 2 encodes a neural-specific transcription factor (NGN2) able to drive neuronal fate on somatic and stem cells. NGN2 is expressed in neural progenitors within the developing central and peripheral nervous systems. Overexpression of NGN2 in human induced pluripotent stem cells (hiPSCs) or human embryonic stem cells has been shown to efficiently trigger conversion to neurons. Here we describe two gene-edited hiPSC lines harbouring a doxycycline (DOX)-inducible cassette in the AAVS1 locus driving expression of NGN2 (BIONi010-C-13) or NGN2-T2A-GFP (BIONi010-C-15). By introducing NGN2-expressing cassette, we reduce variability associated with conventional over-expression methods such as viral transduction, making these lines amenable for scale-up production and screening processes. DOX-treated hiPSCs convert to neural phenotype within one week and display the expression of structural neuronal markers such as Beta-III tubulin and tau. We performed functional characterization of NGN2-neurons co-cultured with hiPSC-derived astrocytes in a "fully-humanized" set up. Passive properties of NGN2-neurons were indistinguishable from mouse primary cells while displaying variable activity in extracellular recordings performed in multi-electrode arrays (MEAs). We demonstrate that hiPSC-derived astrocytes and neurons can be co-cultured and display functional properties comparable to the gold standard used in electrophysiology. Both lines are globally available via EBiSC repository at https://cells.ebisc.org/.
Collapse
Affiliation(s)
- Pei-Yu Shih
- Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Mohamed Kreir
- Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Devesh Kumar
- Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Frederik Seibt
- Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium
| | | | | | - Bjørn Holst
- Bioneer S/A, Kogle Allé 2, 2970 Hørsholm, Denmark
| | | | | | - Benjamin Fischer
- Project Centre for Stem Cell Process Engineering, Fraunhofer Institute for Biomedical Engineering IBMT, Würzburg, Germany
| | | | - Andreas Ebneth
- Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium
| | | |
Collapse
|
6
|
Schmid B, Holst B, Poulsen U, Jørring I, Clausen C, Rasmussen M, Mau-Holzmann UA, Steeg R, Nuthall H, Ebneth A, Cabrera-Socorro A. Generation of two gene edited iPSC-lines carrying a DOX-inducible NGN2 expression cassette with and without GFP in the AAVS1 locus. Stem Cell Res 2021; 52:102240. [PMID: 33610017 DOI: 10.1016/j.scr.2021.102240] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/03/2020] [Revised: 01/20/2021] [Accepted: 02/05/2021] [Indexed: 10/22/2022] Open
Abstract
Neurog2 is the gene encoding the neuronal transcription factor NGN2, which can convert stem cells into functional neurons in a fast and efficient way. Here we report the generation of two iPS cell lines, where DOX inducible constructs of neurog2 either without or with T2A-eGFP were inserted into the safe-site locus AAVS1. These iPS cell lines, BIONi010-C-13 and BIONi010-C-15, respectively, stay pluripotent without DOX but differentiate to (GFP positive) neurons when DOX is added without the need of differentiation factors.
Collapse
Affiliation(s)
| | - Bjørn Holst
- Bioneer A/S, Kogle Alle 2, 2970 Hørsholm, Denmark
| | - Ulla Poulsen
- Bioneer A/S, Kogle Alle 2, 2970 Hørsholm, Denmark
| | - Ida Jørring
- Bioneer A/S, Kogle Alle 2, 2970 Hørsholm, Denmark
| | | | - M Rasmussen
- Bioneer A/S, Kogle Alle 2, 2970 Hørsholm, Denmark
| | - Ulrike A Mau-Holzmann
- Institute of Medical Genetics and Applied Genomics, Division of Cytogenetics, Calwerstrasse 7, University of Tübingen, 72076, Germany
| | | | | | - A Ebneth
- Neuroscience Therapeutic Area, Janssen Research & Development, A Division of Janssen Pharmaceutica NV, UK
| | - A Cabrera-Socorro
- Neuroscience Therapeutic Area, Janssen Research & Development, A Division of Janssen Pharmaceutica NV, UK.
| |
Collapse
|
7
|
Mah N, Seltmann S, Aran B, Steeg R, Dewender J, Bultjer N, Veiga A, Stacey GN, Kurtz A. Access to stem cell data and registration of pluripotent cell lines: The Human Pluripotent Stem Cell Registry (hPSCreg). Stem Cell Res 2020; 47:101887. [PMID: 32707486 DOI: 10.1016/j.scr.2020.101887] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/27/2019] [Accepted: 06/19/2020] [Indexed: 01/15/2023] Open
Abstract
The value of human pluripotent stem cells (hPSC) in regenerative medicine has yet to reach its full potential. The road from basic research tool to clinically validated PSC-derived cell therapy products is a long and winding one, leading researchers, clinicians, industry and regulators alike into undiscovered territory. All stakeholders must work together to ensure the development of safe and effective cell therapies. Similarly, utilization of hPSC in meaningful and controlled disease modeling and drug screening applications requires information on the quality and suitability of the applied cell lines. Central to these common goals is the complete documentation of hPSC data, including the ethical provenance of the source material, the hPSC line derivation, culture conditions and genetic constitution of the lines. Data surrounding hPSC is scattered amongst diverse sources, including publications, supplemental data, researcher lab books, accredited lab reports, certificates of analyses and public data repositories. Not all of these data sources are publicly accessible nor associated with metadata nor stored in a standard manner, such that data can be easily found and retrieved. The Human Pluripotent Stem Cell Registry (hPSCreg; https://hpscreg.eu/) was started in 2007 to impart provenance and transparency towards hPSC research by registering and collecting standard properties of hPSC lines. In this chapter, we present a short primer on the history of stem cell-based products, summarize the ethical and regulatory issues introduced in the course of working with hPSC-derived products and their associated data, and finally present the Human Pluripotent Stem Cell Registry as a valuable resource for all stakeholders in therapies and disease modeling based on hPSC-derived cells.
Collapse
Affiliation(s)
- Nancy Mah
- Berlin-Brandenburger Centrum für Regenerative Therapien (BCRT), Charité - Universitätsmedizin Berlin, Berlin, Germany.
| | - Stefanie Seltmann
- Berlin-Brandenburger Centrum für Regenerative Therapien (BCRT), Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Begoña Aran
- Stem Cell Bank, Regenerative Medicine Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain
| | - Rachel Steeg
- Fraunhofer UK Research Ltd, Technology and Innovation Centre, Glasgow, UK
| | - Johannes Dewender
- Berlin-Brandenburger Centrum für Regenerative Therapien (BCRT), Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Nils Bultjer
- Berlin-Brandenburger Centrum für Regenerative Therapien (BCRT), Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Anna Veiga
- Stem Cell Bank, Regenerative Medicine Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain
| | - Glyn N Stacey
- ISCBI, Barley, UKSSCBio Ltd, Barley, UK; National Stem Cell Resource Centre, Institute of Zoology, Chinese Academy of Sciences, Beijing 100190, China; Innovation Academy for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing 100101, China
| | - Andreas Kurtz
- Berlin-Brandenburger Centrum für Regenerative Therapien (BCRT), Charité - Universitätsmedizin Berlin, Berlin, Germany
| |
Collapse
|
8
|
O'Shea O, Steeg R, Chapman C, Mackintosh P, Stacey GN. Development and implementation of large-scale quality control for the European bank for induced Pluripotent Stem Cells. Stem Cell Res 2020; 45:101773. [DOI: 10.1016/j.scr.2020.101773] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/26/2019] [Revised: 03/04/2020] [Accepted: 03/14/2020] [Indexed: 01/11/2023] Open
|
9
|
Kim JH, Alderton A, Crook JM, Benvenisty N, Brandsten C, Firpo M, Harrison PW, Kawamata S, Kawase E, Kurtz A, Loring JF, Ludwig T, Man J, Mountford JC, Turner ML, Oh S, da Veiga Pereira L, Pranke P, Sheldon M, Steeg R, Sullivan S, Yaffe M, Zhou Q, Stacey GN. A Report from a Workshop of the International Stem Cell Banking Initiative, Held in Collaboration of Global Alliance for iPSC Therapies and the Harvard Stem Cell Institute, Boston, 2017. Stem Cells 2019; 37:1130-1135. [PMID: 31021472 PMCID: PMC7187460 DOI: 10.1002/stem.3003] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2018] [Revised: 01/07/2019] [Accepted: 01/10/2019] [Indexed: 01/16/2023]
Abstract
This report summarizes the recent activity of the International Stem Cell Banking Initiative held at Harvard Stem Cell Institute, Boston, MA, USA, on June 18, 2017. In this meeting, we aimed to find consensus on ongoing issues of quality control (QC), safety, and efficacy of human pluripotent stem cell banks and their derivative cell therapy products for the global harmonization. In particular, assays for the QC testing such as pluripotency assays test and general QC testing criteria were intensively discussed. Moreover, the recent activities of global stem cell banking centers and the regulatory bodies were briefly summarized to provide an overview on global developments and issues. stem cells2019;37:1130–1135
Collapse
Affiliation(s)
- Jung-Hyun Kim
- Division of Intractable Diseases, Korea National Stem Cell Bank, Center for Biomedical Sciences, Korea National Institute of Health, Cheongju, Korea
| | - Alex Alderton
- Wellcome Sanger Institute, Cambridge, United Kingdom
| | - Jeremy M Crook
- ARC Centre of Excellence for Electromaterials Science, Intelligent Polymer Research Institute, AIIM Facility, University of Wollongong, Wollongong, Australia.,Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, Australia.,Department of Surgery, St Vincent's Hospital, The University of Melbourne, Melbourne, Australia
| | - Nissim Benvenisty
- The Azrieli Center for Stem Cells and Genetic Research, Institute of Life Sciences, Hebrew University of Jerusalem, Jerusalem, Israel
| | | | - Meri Firpo
- Cell Line Development Memphis Meats, Berkeley, California, USA.,University of Minnesota, Minneapolis, Minnesota, USA
| | - Peter W Harrison
- European Bioinformatics Institute (EMBL-EBI), Cambridge, United Kingdom
| | - Shin Kawamata
- Foundation for Biological Research and Innovation (FBRI), Kobe, Japan
| | - Eihachiro Kawase
- Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan
| | - Andreas Kurtz
- Berlin-Brandenburg Center for Regenerative Therapies, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Jeanne F Loring
- Center for Regenerative Medicine, Department of Chemical Physiology, The Scripps Research Institute, La Jolla, California, USA
| | - Tenneille Ludwig
- WiCell Research Institute, WiCell Stem Cell Bank, Madison, Wisconsin, USA
| | - Jennifer Man
- UK Stem Cell Bank, National Institute for Biological Standards and Control, South Mimms, United Kingdom.,Adaptimmune Ltd., Abingdon, United Kingdom
| | - Joanne C Mountford
- Advanced Therapeutics, Scottish National Blood Transfusion Service, Edinburgh, United Kingdom
| | - Marc L Turner
- Advanced Therapeutics, Scottish National Blood Transfusion Service, Edinburgh, United Kingdom.,Cell & Gene Therapy Catapult, Guy's Hospital, London, United Kingdom.,The Jack Copland Centre, Global Alliance for iPSC Therapies (GAiT), Edinburgh, United Kingdom
| | - Steve Oh
- National Laboratory for Embryonic Stem Cells (LaNCE), Department of Genetics and Evolutionary Biology, Biosciences Institute, University of São Paulo, São Paulo, Brazil
| | - Lygia da Veiga Pereira
- Hematology and Stem Cell Laboratory, Faculty of Pharmacy, Universidade Federal do Rio Grande do Sul. Stem Cell Research Institute, Porto Alegre, Brazil
| | - Patricia Pranke
- Department of Genetics, Rutgers, The State University of New Jersey, Piscataway, New Jersey, USA
| | - Michael Sheldon
- Roslin Innovation Centre, Censo Biotechnologies Ltd, Midlothian, United Kingdom
| | - Rachel Steeg
- Stem Cell Group, Bioprocessing Technology Institute, Singapore, Singapore
| | - Stephen Sullivan
- The Jack Copland Centre, Global Alliance for iPSC Therapies (GAiT), Edinburgh, United Kingdom
| | - Michael Yaffe
- New York Stem Cell Foundation, New York, New York, USA
| | - Qi Zhou
- State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, People's Republic of China
| | - Glyn N Stacey
- International Stem Cell Banking Initiative, Royston, United Kingdom
| |
Collapse
|
10
|
De Sousa PA, Steeg R, Kreisel B, Allsopp TE. Hot Start to European Pluripotent Stem Cell Banking. Trends Biotechnol 2017; 35:573-576. [PMID: 28511937 DOI: 10.1016/j.tibtech.2017.04.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2017] [Revised: 04/12/2017] [Accepted: 04/14/2017] [Indexed: 12/17/2022]
Abstract
Achieving consistency in standards of access to and quality of human induced pluripotent stem cells has lagged behind their use. In Europe, a network of academic and industrial partners has been established to overcome this challenge. The experience reveals the devil in the detail of worthy ambitions informing future efforts.
Collapse
Affiliation(s)
- Paul A De Sousa
- Centre for Clinical Brain Sciences, Chancellors Building, 49 Little France Crescent, University of Edinburgh, Edinburgh EH16 4SB, UK; Roslin Cells Ltd, Head Office, Nine Edinburgh BioQuarter, 9 Little France Road, Edinburgh EH16 4UX, UK; EBiSC Banking Facility, Babraham Research Campus, B260 Meditrina, Cambridge CB22 3AT, UK.
| | - Rachel Steeg
- Roslin Cells Ltd, Head Office, Nine Edinburgh BioQuarter, 9 Little France Road, Edinburgh EH16 4UX, UK; EBiSC Banking Facility, Babraham Research Campus, B260 Meditrina, Cambridge CB22 3AT, UK
| | - Beate Kreisel
- ARTTIC, 58A rue du Dessous des Berges, F-75013 Paris, France
| | - Timothy E Allsopp
- Pfizer Ltd (Neusentis),The Portway Building, Granta Park, Great Abington, Cambridge CB21 6GS, UK; Current affiliation Consilium Bio Ltd, Suffolk, IP33 3TJ, UK
| |
Collapse
|
11
|
De Sousa PA, Steeg R, Wachter E, Bruce K, King J, Hoeve M, Khadun S, McConnachie G, Holder J, Kurtz A, Seltmann S, Dewender J, Reimann S, Stacey G, O'Shea O, Chapman C, Healy L, Zimmermann H, Bolton B, Rawat T, Atkin I, Veiga A, Kuebler B, Serano BM, Saric T, Hescheler J, Brüstle O, Peitz M, Thiele C, Geijsen N, Holst B, Clausen C, Lako M, Armstrong L, Gupta SK, Kvist AJ, Hicks R, Jonebring A, Brolén G, Ebneth A, Cabrera-Socorro A, Foerch P, Geraerts M, Stummann TC, Harmon S, George C, Streeter I, Clarke L, Parkinson H, Harrison PW, Faulconbridge A, Cherubin L, Burdett T, Trigueros C, Patel MJ, Lucas C, Hardy B, Predan R, Dokler J, Brajnik M, Keminer O, Pless O, Gribbon P, Claussen C, Ringwald A, Kreisel B, Courtney A, Allsopp TE. Rapid establishment of the European Bank for induced Pluripotent Stem Cells (EBiSC) - the Hot Start experience. Stem Cell Res 2017; 20:105-114. [PMID: 28334554 DOI: 10.1016/j.scr.2017.03.002] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/17/2016] [Revised: 02/17/2017] [Accepted: 03/03/2017] [Indexed: 10/20/2022] Open
Abstract
A fast track "Hot Start" process was implemented to launch the European Bank for Induced Pluripotent Stem Cells (EBiSC) to provide early release of a range of established control and disease linked human induced pluripotent stem cell (hiPSC) lines. Established practice amongst consortium members was surveyed to arrive at harmonised and publically accessible Standard Operations Procedures (SOPs) for tissue procurement, bio-sample tracking, iPSC expansion, cryopreservation, qualification and distribution to the research community. These were implemented to create a quality managed foundational collection of lines and associated data made available for distribution. Here we report on the successful outcome of this experience and work flow for banking and facilitating access to an otherwise disparate European resource, with lessons to benefit the international research community. ETOC: The report focuses on the EBiSC experience of rapidly establishing an operational capacity to procure, bank and distribute a foundational collection of established hiPSC lines. It validates the feasibility and defines the challenges of harnessing and integrating the capability and productivity of centres across Europe using commonly available resources currently in the field.
Collapse
Affiliation(s)
- Paul A De Sousa
- Centre for Clinical Brain Sciences, Chancellors Building, 49 Little France Crescent, University of Edinburgh, Edinburgh EH16 4SB, UK; Roslin Cells Ltd(1), Head office, Nine Edinburgh Bioquarter, 9 Little France Rd, Edinburgh EH16 4UX, UK; EBiSC banking facility, Babraham Research Campus, B260 Meditrina, Cambridge CB22 3AT, UK.
| | - Rachel Steeg
- Roslin Cells Ltd(1), Head office, Nine Edinburgh Bioquarter, 9 Little France Rd, Edinburgh EH16 4UX, UK; EBiSC banking facility, Babraham Research Campus, B260 Meditrina, Cambridge CB22 3AT, UK
| | - Elisabeth Wachter
- Roslin Cells Ltd(1), Head office, Nine Edinburgh Bioquarter, 9 Little France Rd, Edinburgh EH16 4UX, UK; EBiSC banking facility, Babraham Research Campus, B260 Meditrina, Cambridge CB22 3AT, UK
| | - Kevin Bruce
- Roslin Cells Ltd(1), Head office, Nine Edinburgh Bioquarter, 9 Little France Rd, Edinburgh EH16 4UX, UK; EBiSC banking facility, Babraham Research Campus, B260 Meditrina, Cambridge CB22 3AT, UK
| | - Jason King
- Roslin Cells Ltd(1), Head office, Nine Edinburgh Bioquarter, 9 Little France Rd, Edinburgh EH16 4UX, UK; EBiSC banking facility, Babraham Research Campus, B260 Meditrina, Cambridge CB22 3AT, UK
| | - Marieke Hoeve
- Roslin Cells Ltd(1), Head office, Nine Edinburgh Bioquarter, 9 Little France Rd, Edinburgh EH16 4UX, UK; EBiSC banking facility, Babraham Research Campus, B260 Meditrina, Cambridge CB22 3AT, UK
| | - Shalinee Khadun
- Roslin Cells Ltd(1), Head office, Nine Edinburgh Bioquarter, 9 Little France Rd, Edinburgh EH16 4UX, UK; EBiSC banking facility, Babraham Research Campus, B260 Meditrina, Cambridge CB22 3AT, UK
| | - George McConnachie
- Roslin Cells Ltd(1), Head office, Nine Edinburgh Bioquarter, 9 Little France Rd, Edinburgh EH16 4UX, UK; EBiSC banking facility, Babraham Research Campus, B260 Meditrina, Cambridge CB22 3AT, UK
| | - Julie Holder
- Roslin Cells Ltd(1), Head office, Nine Edinburgh Bioquarter, 9 Little France Rd, Edinburgh EH16 4UX, UK; EBiSC banking facility, Babraham Research Campus, B260 Meditrina, Cambridge CB22 3AT, UK
| | - Andreas Kurtz
- Charité - Universitätsmedizin Berlin, Berlin-Brandenburg Center for Regenerative Therapies, Augustenburger Platz, Berlin 13353, Germany
| | - Stefanie Seltmann
- Charité - Universitätsmedizin Berlin, Berlin-Brandenburg Center for Regenerative Therapies, Augustenburger Platz, Berlin 13353, Germany
| | - Johannes Dewender
- Charité - Universitätsmedizin Berlin, Berlin-Brandenburg Center for Regenerative Therapies, Augustenburger Platz, Berlin 13353, Germany
| | - Sascha Reimann
- Charité - Universitätsmedizin Berlin, Berlin-Brandenburg Center for Regenerative Therapies, Augustenburger Platz, Berlin 13353, Germany
| | - Glyn Stacey
- UK Stem Cell Bank, Division of Advanced Therapies, National Institute for Biological Standards and Control, Medicines and Healthcare Products Regulatory Authority, Blanche Lane, South Mimms, Hertfordshire, ENG 3GQ, UK
| | - Orla O'Shea
- UK Stem Cell Bank, Division of Advanced Therapies, National Institute for Biological Standards and Control, Medicines and Healthcare Products Regulatory Authority, Blanche Lane, South Mimms, Hertfordshire, ENG 3GQ, UK
| | - Charlotte Chapman
- UK Stem Cell Bank, Division of Advanced Therapies, National Institute for Biological Standards and Control, Medicines and Healthcare Products Regulatory Authority, Blanche Lane, South Mimms, Hertfordshire, ENG 3GQ, UK
| | - Lyn Healy
- UK Stem Cell Bank, Division of Advanced Therapies, National Institute for Biological Standards and Control, Medicines and Healthcare Products Regulatory Authority, Blanche Lane, South Mimms, Hertfordshire, ENG 3GQ, UK
| | - Heiko Zimmermann
- Fraunhofer Institute for Biomedical Engineering (IBMT), Josef-von-Fraunhofer-Weg 1, 66280 Sulzbach, Germany; Molecular & Cellular Biotechnology/Nanotechnology, Saarland University, Campus, 66123 Saarbrücken, Germany
| | - Bryan Bolton
- European Collection of Authenticated Cell Cultures, Public Health England, Porton Down, Salisbury SP4 0JG, UK
| | - Trisha Rawat
- European Collection of Authenticated Cell Cultures, Public Health England, Porton Down, Salisbury SP4 0JG, UK
| | - Isobel Atkin
- European Collection of Authenticated Cell Cultures, Public Health England, Porton Down, Salisbury SP4 0JG, UK
| | - Anna Veiga
- Barcelona Stem Cell Bank, Centre for Regenerative Medicine in Barcelona, C/Dr. Aiguader 88, 08003 Barcelona, Spain
| | - Bernd Kuebler
- Barcelona Stem Cell Bank, Centre for Regenerative Medicine in Barcelona, C/Dr. Aiguader 88, 08003 Barcelona, Spain
| | - Blanca Miranda Serano
- Andalusian Public Health Care System, Avda Conocimiento sn, 18100 Armilla, Granada, Spain
| | - Tomo Saric
- Centre for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty, University of Cologne, 50931 Cologne, Germany
| | - Jürgen Hescheler
- Centre for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty, University of Cologne, 50931 Cologne, Germany
| | - Oliver Brüstle
- Institute of Reconstructive Neurobiology, LIFE & BRAIN Centre, University of Bonn, Sigmund-Freud-Strasse 25, 53105 Bonn, Germany
| | - Michael Peitz
- Institute of Reconstructive Neurobiology, LIFE & BRAIN Centre, University of Bonn, Sigmund-Freud-Strasse 25, 53105 Bonn, Germany
| | - Cornelia Thiele
- Institute of Reconstructive Neurobiology, LIFE & BRAIN Centre, University of Bonn, Sigmund-Freud-Strasse 25, 53105 Bonn, Germany
| | - Niels Geijsen
- Hubrecht Institute for developmental biology and stem cell research, Royal Netherlands Academy of Arts and Sciences (KNAW), Utrecht University, Department of Clinical Sciences of Companion Animals and UMC Utrecht, 3584CT Utrecht, The Netherlands
| | - Bjørn Holst
- Bioneer A/S, Kogle Alle 2, DK-2970 Hørsholm, Denmark
| | | | - Majlinda Lako
- Institute for Genetic Medicine, University of Newcastle, Newcastle NE1 3BZ, United Kingdom
| | - Lyle Armstrong
- Institute for Genetic Medicine, University of Newcastle, Newcastle NE1 3BZ, United Kingdom
| | - Shailesh K Gupta
- AstraZeneca, R&D, Innovative Medicines, Discovery Sciences, Reagents and Assay Development, HC3006, Pepparedsleden 1, SE-431 83 Mölndal, Sweden
| | - Alexander J Kvist
- AstraZeneca, R&D, Innovative Medicines, Discovery Sciences, Reagents and Assay Development, HC3006, Pepparedsleden 1, SE-431 83 Mölndal, Sweden
| | - Ryan Hicks
- AstraZeneca, R&D, Innovative Medicines, Discovery Sciences, Reagents and Assay Development, HC3006, Pepparedsleden 1, SE-431 83 Mölndal, Sweden
| | - Anna Jonebring
- AstraZeneca, R&D, Innovative Medicines, Discovery Sciences, Reagents and Assay Development, HC3006, Pepparedsleden 1, SE-431 83 Mölndal, Sweden
| | - Gabriella Brolén
- AstraZeneca, R&D, Innovative Medicines, Discovery Sciences, Reagents and Assay Development, HC3006, Pepparedsleden 1, SE-431 83 Mölndal, Sweden
| | - Andreas Ebneth
- Janssen Research & Development (A Division of Janssen Pharmaceutica N.V), Neuroscience Therapeutic Area, Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Alfredo Cabrera-Socorro
- Janssen Research & Development (A Division of Janssen Pharmaceutica N.V), Neuroscience Therapeutic Area, Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Patrik Foerch
- UCB Biopharma (since May 2014), Discovery Research, Chemin du Foriest, Braine l'Alleud B-1420, Belgium
| | - Martine Geraerts
- UCB Biopharma (since May 2014), Discovery Research, Chemin du Foriest, Braine l'Alleud B-1420, Belgium
| | | | - Shawn Harmon
- University of Edinburgh School of Law, Old College, South Bridge, Edinburgh EH8 9YL, UK
| | - Carol George
- University of Edinburgh School of Law, Old College, South Bridge, Edinburgh EH8 9YL, UK
| | - Ian Streeter
- European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK
| | - Laura Clarke
- European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK
| | - Helen Parkinson
- European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK
| | - Peter W Harrison
- European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK
| | - Adam Faulconbridge
- European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK
| | - Luca Cherubin
- European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK
| | - Tony Burdett
- European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK
| | - Cesar Trigueros
- Inbiomed, P° Mikeletegi, 81, 20009 San Sebastián, Gipuzkoa, Spain
| | - Minal J Patel
- Cellular Generation and Phenotyping (CGaP) facility, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinston CB10 1SA, UK
| | - Christa Lucas
- Cellular Generation and Phenotyping (CGaP) facility, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinston CB10 1SA, UK
| | - Barry Hardy
- Douglas Connect, Technology Park Basel, Hochbergerstrasse 60C, 4057 Basel, Switzerland
| | - Rok Predan
- Douglas Connect, Technology Park Basel, Hochbergerstrasse 60C, 4057 Basel, Switzerland
| | - Joh Dokler
- Douglas Connect, Technology Park Basel, Hochbergerstrasse 60C, 4057 Basel, Switzerland
| | - Maja Brajnik
- Douglas Connect, Technology Park Basel, Hochbergerstrasse 60C, 4057 Basel, Switzerland
| | - Oliver Keminer
- Fraunhofer IME ScreeningPort, Schnackenburgallee 114, D-22525 Hamburg, Germany
| | - Ole Pless
- Fraunhofer IME ScreeningPort, Schnackenburgallee 114, D-22525 Hamburg, Germany
| | - Philip Gribbon
- Fraunhofer IME ScreeningPort, Schnackenburgallee 114, D-22525 Hamburg, Germany
| | - Carsten Claussen
- Fraunhofer IME ScreeningPort, Schnackenburgallee 114, D-22525 Hamburg, Germany
| | | | - Beate Kreisel
- ARTTIC, 58A rue du Dessous des Berges, F-75013 Paris, France
| | - Aidan Courtney
- Roslin Cells Ltd(1), Head office, Nine Edinburgh Bioquarter, 9 Little France Rd, Edinburgh EH16 4UX, UK; EBiSC banking facility, Babraham Research Campus, B260 Meditrina, Cambridge CB22 3AT, UK
| | - Timothy E Allsopp
- Pfizer Ltd (Neusentis), The Portway Building, Granta Park, Great Abington, Cambridge, CB21 6GS, UK
| |
Collapse
|